Antisecretory effect of oral targeted therapies in advanced functioning neuroendocrine tumors (the ASSET-NET study)

#3377

Introduction: Oral targeted therapies (TTs),everolimus and sunitinib,have demonstrated antitumor activity in patients with advanced progressive neuroendocrine tumors (NETs).

Aim(s): To describe the antisecretory efficacy of TTs on uncontrolled secretory syndromes in patients with advanced functioning NETs.

Materials and methods: Patients were included if they were diagnosed with advanced NET and treated by oral TT (everolimus or sunitinib) for progressive disease with uncontrolled clinical secretory syndrome between January 2010 to January 2021. Data on NET characteristics and morphological response were collected. The clinical course of secretory syndrome during TT was evaluated at baseline, at first reevaluation (within 15 days), at one month, and at symptoms worsening. The primary outcome was the clinical response rate (CRR).

Conference:

Presenting Author:

Authors: Perrier M, Walter T, Do Cao C, Coriat R, Haissaguerre M,

Keywords: functional syndrome, targeted therapy, neuroendocrine tumor, antisecretory effect,